Trial Profile
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without Bevacizumab in Platinum-resistant ovarian cancer patients previously treated with Bevacizumab for front-line or Platinum-sensitive ovarian cancer: -JGOG3023 trial-
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal; Gemcitabine; Paclitaxel; Topotecan
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms JGOG3023 trial
- 01 Jan 2022 Primary endpoint (Progression-free survival:PFS) has been met, as per results published in the Cancer Science.
- 01 Jan 2022 Results assessing the efficacy and safety of further bevacizumab therapy in patients with platinum-resistant ovarian cancer whose disease had progressed after bevacizumab plus chemotherapy, published in the Cancer Science.
- 13 Dec 2021 Status changed from active, no longer recruiting to completed.